User:Tkadm30/Notebook/Endocannabinoids/Anandamide

Intracellular anandamide trafficking as a promoter of neurogenesis acting through presynaptic CB1/FABP binding

The maturation and differentiation of neural stem cells via fatty-acid binding proteins (FABPs) signaling may require anandamide as a promoter of CB1-dependent neurogenesis. [1]

Hippocampal neurogenesis with synaptogenic promoter (DHA) is induced by intracellular and presynaptic CB1 receptor binding to anandamide. [2]

Notes

• The allosteric activation of PPAR-RXR heterodimer by anandamide (CB1/TRPV1 receptors) may facilitate hippocampal neurogenesis. (Reference needed)
• Intracellular FABP5 expression may result in anandamide trafficking of heteromeric CB1 receptor. (Reference needed)
• Adenosine antagonism (caffeine) may potentiate retrograde trafficking of anandamide via heteromization of CB1 receptor. (Reference needed)
• Anandamide biosynthesis may enhance caffeine-induced diuresis. [3]
• Anandamide-oxytocin cross-talk (signal transduction) may modulate cellular stress response/vitamin D gene expression?

See also

• TRPV1 Notebook
• Oxytocin Notebook
• Anandamide (Wikipedia)

References

1. https://www.ncbi.nlm.nih.gov/pubmed/23372698

   Type-1 (CB1) Cannabinoid Receptor Promotes Neuronal Differentiation and Maturation of Neural Stem Cells

2. https://www.ncbi.nlm.nih.gov/pubmed/21719698

   Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide.

3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533417/

   Diuretic Effects of Cannabinoids

4. https://www.ncbi.nlm.nih.gov/pubmed/18832445

   The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway.

5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC20983/

   The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.